Karyopharm Therapeutics

NCT07479979

Collaborator, Phase 1/2, Recruiting, 2026, 62 people, 18 Mar 2026, clinicaltrials.gov

NCT06399640

Collaborator, Phase 1, Recruiting, 2024, 60 people, 6 May 2024, clinicaltrials.gov

NCT05980806

Phase 2, Recruiting, 2024, 58 people, 8 Aug 2023, clinicaltrials.gov

NCT05820763

Collaborator, Phase 2, Withdrawn, 2024, 0 people, 20 Apr 2023, clinicaltrials.gov

NCT05530421

Collaborator, Phase 2, Recruiting, 2023, 33 people, 7 Sept 2022, clinicaltrials.gov

NCT05170789

Collaborator, Phase 2, Withdrawn, 2022, 0 people, 28 Dec 2021, clinicaltrials.gov

NCT05028348

Collaborator, Phase 3, Active, not recruiting, 2022, 117 people, 31 Aug 2021, clinicaltrials.gov

NCT04984330

Collaborator, Early phase 1, Withdrawn, 2021, 0 people, 30 Jul 2021, clinicaltrials.gov

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Collaborator, Phase 2, Active, not recruiting, 2021, 18 people, 14 Jun 2021, clinicaltrials.gov

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Collaborator, Phase 1, Active, not recruiting, 2021, 37 people, 24 May 2021, clinicaltrials.gov

NCT04843579

Collaborator, Phase 2, Terminated, 2021, 4 people, 13 Apr 2021, clinicaltrials.gov

NCT04782687

Collaborator, Phase 2, Active, not recruiting, 2021, 73 people, 4 Mar 2021, clinicaltrials.gov

NCT04717700

Collaborator, Phase 2, Active, not recruiting, 2021, 50 people, 22 Jan 2021, clinicaltrials.gov

NCT04661137

Collaborator, Phase 2, Recruiting, 2021, 96 people, 10 Dec 2020, clinicaltrials.gov

NCT04607772

Phase 1/2, Withdrawn, 2020, 0 people, 29 Oct 2020, clinicaltrials.gov

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

Phase 3, Active, not recruiting, 2021, 353 people, 24 Sept 2020, clinicaltrials.gov

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2/3, Active, not recruiting, 2020, 501 people, 22 Jun 2020, clinicaltrials.gov

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Phase 2, Recruiting, 2020, 127 people, 4 Jun 2020, clinicaltrials.gov

NCT03955783

Collaborator, Phase 1, Completed, 2019, 78 people, 20 May 2019, clinicaltrials.gov

NCT03732703

Collaborator, Phase 1/2, Completed, 2019, 103 people, 7 Nov 2018, clinicaltrials.gov